|Bid||2.20 x 1500|
|Ask||2.75 x 400|
|Day's Range||2.30 - 2.41|
|52 Week Range||2.00 - 9.35|
|PE Ratio (TTM)||-1.12|
|Earnings Date||Jul 31, 2017 - Aug 4, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Boulder, Colorado-based company said it had a loss of 24 cents. Losses, adjusted for restructuring costs, were 18 cents per share. The results exceeded Wall Street expectations. ...
ImmunoGen has made significant progress with its ovarian cancer pipeline candidate. Let's see if the company can come up with a beat this earnings season.
Nivalis Therapeutics, Inc. announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held July 19, 2017, its stockholders approved all of the merger-related proposals, including: the Agreement and Plan of Merger and Reorganization, dated as of April 18, 2017, by and among Nivalis, Nautilus Merger Sub, Inc.